Cytokine gene expression in cells derived from CSF of multiple sclerosis patients

Journal of Neuroimmunology

Volumn 89, Issue 1-2, 1998, Pages 198-205

  Calabresi, P A ^a   Tranquill, L R ^b   McFarland, H F ^b   Cowan, E P ^c  

^a RHODE ISLAND HOSPITAL   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Interferon; Interleukin; MRI; PCR; Tumor necrosis factor

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DEMYELINATING DISEASE; DISEASE ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTISENSE ELEMENTS (GENETICS); CEREBROSPINAL FLUID; CYTOKINES; FEMALE; GENE EXPRESSION; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-4; LEUKOCYTES; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032516799     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00139-8     Document Type: Article

References (27)

1. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37:1995;424-435.
2. Chabot S., Williams G., Yong V. Microglial production of TNF-α is induced by activated T lymphocytes. J. Clin. Inv. 100:1997;604-612.
3. Filippi M., Horsfield M.A., Tofts P.S., Barkhof F., Thompson A.J., Miller D.H. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain. 118:1995;1601-1612.
4. Hemmer B., Vergelli M., Calabresi P.A., Huang T., McFarland H., Martin R. Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin protein peptide. J. Neurologic Sci. 45:1996;852-862.
5. Katz D., Taubenberger J.K., Cannella B., McFarlin D.E., Raine C.S., McFarland H.F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann. Neurol. 34:1993;661-669.
6. Kennedy M.K., Torrance D.S., Picha K.S., Mohler K.M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:1992;2496-2505.
7. Kermode A.G., Thompson J.A., Tofts P.S., MacManus D.G., Kendall B.E., Kingsley D.P.E., Moseley I.F., Rudge P., McDonald W.I. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenesis and clinical implications. Brain. 113:1990;1477-1489.
8. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
9. Leppert D., Waubant E., Burk M.R., Oksenberg J., Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1996;846-852.
10. Link J., Soderstrom M., Olsson T., Hojeberg B., Ljungdahl A., Link H. Increased transforming growth factor-β, interleukin-4 and interferon-γ in multiple sclerosis. Ann. Neurol. 36:1994;379-386.
11. Martin R., McFarland H.F. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci. 32:1995;121-182.
12. Matusevicius D., Navikas V., Soderstrom M., Xiao B.G., Haglund M., Fredrikson S., Link H. Multiple sclerosis: the pro-inflammatory cytokines lymphotoxin-alpha and tumor necrosis factor-alpha are upregulated in cerebrospinal fluid mononuclear cells. J. Neuroimmunol. 66:1996;115-123.
13. McFarland H.F., Frank J.A., Albert P.S., Smith M.E., Martin R., Harris J.O., Patronas N., Maloni H., McFarlin D.E. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann. Neurol. 32:1992;758-766.
14. Navikas V., Matusevicius D., Soderstrom M., Fredrikson S., Kivisakk P., Ljungdahl A., Hojeberg B., Link H. Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. J. Neuroimmunol. 64:1996;63-69.
15. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
16. Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., Shevach E.M., Rocken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1994;1961-1966.
17. Racke M.K., Burnett D., Pak S.H., Albert P.S., Cannella B., Raine C.S., McFarlin D.E., Scott D.E. Retinoid treatment of experimental allergic encephalomyelitis: IL-4 production correlates with improved disease course. J.Immunol. 154:1995;450-458.
18. Raine C.S. Multiple sclerosis: immune system molecule expression in the central nervous system. J. Neuropathol. Exp. Neurol. 53:1994;328-337.
19. Renno T., Lin J., Piccirillo C., Antel J., Owens T. Cytokine production by cells in cerebrospinal fluid during experimental allergic encephalomyelitis in SJL/J mice. J. Neuroimmunol. 49:1994;1-7.
20. Rovaris M., Barnes D., Woodrofe N., du Boulay G.H., Thorpe J.W., Thompson A.J., McDonald W.I., Miller D.H. Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. J. Neurology. 243:1996;536-542.
21. Rudick R.A., Ransohoff R.M., Peppler R., VanderBrug Medendorp S., Lehmann P., Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol. 40:1996;618-627.
22. Sharief M.K., Hentges R. Association between tumor necrosis factor-α and disease progression in chronic progressive multiple sclerosis. N. Eng. J. Med. 325:1991;467-472.
23. Smith M.E., Stone L.A., Albert P.S., Frank J.A., Martin R., Armstrong M., Maloni H., McFarlin D.E., McFarland H.F. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadolinium enhancing MRI lesions. Ann. Neurol. 33:1993;480-489.
24. Spuler S., Yousry T., Scheller A., Voltz R., Holler E., Hartmann M., Wick M., Hohlfield R. Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J. Neuroimmunol. 66:1996;57-64.
25. Stone L.A., Frank J.A., Albert P.S., Bash C.N., Maloni H., McFarland H.F. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol. 37:1995;611-619.
26. Stuve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., Yong V.W. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40:1996;853-863.
27. Zamvil S.S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8:1990;579-621.